Keywords
pacemaker
cardioverter-defibrillator
How to Cite
Abstract
Background. Due to the ageing population and effective treatment of primary and secondary cardiovascular events, an epidemic of heart failure can be observed. Optimal treatment of the disease based on current guidelines and scientific data includes education, lifestyle modification, pharmacotherapy and cardiac resynchronisation device implantation Objectives. The aim of this study was to provide an answer to the question whether or not and, if yes, then to what extent, the life quality of patients after cardiac resynchronisation device implantation is affected after no less than 6 months following the procedure, and what factors contribute to this change. Material and methods. The study involved 21 patients (17 men) aged 54 to 81 years (the average: 68.86). QoL was evaluated with the Polish version of the World Health Organization Quality of Life Questionnaire WHOQoL-BREF, separately for individuals up to 65 and over 65 years of age. Results. The somatic and psychological areas of life quality evaluation were homogeneous in the age subgroups compared, while the social and environment areas were not. Prior to the surgery, the WHOQoL-BREF scores in social sphere were significantly higher in younger patients. Post-surgery, much better results in the environmental sphere were recorded for older patients. The implantation of the cardiac resynchronisation device had a positive impact in all four areas of life quality. Conclusions. In conclusion, our study revealed that resynchronisation therapy helps to improve patients’ overall quality of life. The therapy had a positive impact on the perceived somatic, psychological and social area in each patient group, both up to 65 and over 65 years of age.References
WHO. The World Health Organization Quality of Life assessment (WHOQoL): position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403–1409.
McMurray J, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847.
Daubert C, Gol MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009; 54: 1837–1846.
Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011; 123: 1159–1166.
Saxena S, Carlson D, Billington R, et al. The WHO quality of life assessment instrument (WHOQoL-Bref): the importance of its items for cross-cultural research. Qual Life Res 2011; 10: 711–721.
Solomon SD, Foster E, Bourgoun M, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation 2010; 122: 985–992.
Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Failure 2000; 6: 276–285.
Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002; 40: 111–118.
Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289: 2685–2694.
Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27: 1928–1932.
Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42: 1454–1459.
Karasek D, Kubica A, Sinkiewicz W, et al. An epidemic of heart failure; health and social problem of ageing populations in Poland and Europe. Folia Cardiol Excep 2008; 3: 242–248.
Jurgiewicz-Szyguła B, Kowalska M, Mościński M. Quality of life as a factor of the evaluation of health and treatment effectiveness in patients with cardiovascular system diseases. Folia Cardiol Excep 2011; 6: 62–71.